Medications for Substance Use Disorders

被引：38

作者：

Douaihy, Antoine B. ^{[1
]}

Kelly, Thomas M. ^{[2
]}

Sullivan, Carl ^{[3
]}

机构：

[1] Univ Pittsburgh, Dept Psychiat, Western Psychiat Inst & Clin, Sch Med, Pittsburgh, PA 15213 USA

[2] Univ Pittsburgh, Ctr Psychiat & Chem Dependency Serv, Med Ctr, Pittsburgh, PA 15213 USA

[3] W Virginia Univ, Addict Program, Morgantown, WV 26506 USA

来源：

SOCIAL WORK IN PUBLIC HEALTH | 2013年 / 28卷 / 3-4期

关键词：

Substance use disorders; detoxification; relapse prevention; nicotine; alcohol; opioids; social workers; SUSTAINED-RELEASE BUPROPION; PLACEBO-CONTROLLED TRIAL; RECEPTOR PARTIAL AGONIST; ALCOHOL-DEPENDENCE; SMOKING-CESSATION; DOUBLE-BLIND; NALTREXONE; EFFICACY; PHARMACOTHERAPY; DISULFIRAM;

D O I：

10.1080/19371918.2013.759031

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

In this article, the authors briefly review the pharmacotherapeutic agents that are currently available for the treatment of substance use disorders. Nicotine replacement therapies are most effective for tobacco cessation. Naltrexone, acamprosate, and disulfiram are effective for reducing alcohol use. The most effective pharmacotherapies for opiate use disorders are agonist therapies, including methadone and buprenorphine. The authors also examine recent advances in medication development for other substance use disorders such as stimulant addiction. The role of medication adherence and behavioral treatments and the integration of behavioral and pharmacotherapeutic interventions are also discussed.

引用

下载

页码：264 / 278

页数：15

共 50 条

[1] New Medications for Substance Use Disorders: Challenges and Opportunities
Volkow, Nora D.
Skolnick, Phil
NEUROPSYCHOPHARMACOLOGY, 2012, 37 (01) : 290 - 292
[2] Medications for substance use disorders (SUD): emerging approaches
Butelman, Eduardo R.
Kreek, Mary Jeanne
EXPERT OPINION ON EMERGING DRUGS, 2017, 22 (04) : 301 - 315
[3] New Medications for Substance Use Disorders: Challenges and Opportunities
Nora D Volkow
Phil Skolnick
Neuropsychopharmacology, 2012, 37 : 290 - 292
[4] MEDICATIONS AGAINST DRUGS Development of medications to prevent and treat substance use disorders
Montoya, Iven D.
METODE SCIENCE STUDIES JOURNAL, 2022, (12): : 87 - 93
[5] OPPORTUNITIES FOR TREATMENT OF PSYCHOACTIVE SUBSTANCE USE DISORDERS WITH SEROTONERGIC MEDICATIONS
SELLERS, EM
HIGGINS, GA
TOMKINS, DM
ROMACH, MK
TONEATTO, T
JOURNAL OF CLINICAL PSYCHIATRY, 1991, 52 : 49 - 54
[6] Pharmacotherapeutics for substance-use disorders: a focus on dopaminergic medications
Verrico, Christopher D.
Haile, Colin N.
Newton, Thomas F.
Kosten, Thomas R.
De La Garza, Richard
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2013, 22 (12) : 1549 - 1568
[7] Health Insurance Enrollment and Availability of Medications for Substance Use Disorders
Abraham, Amanda J.
Rieckmann, Traci
Andrews, Christina M.
Jayawardhana, Jayani
PSYCHIATRIC SERVICES, 2017, 68 (01) : 41 - 47
[8] IUPHAR Review: New strategies for medications to treat substance use disorders
Montoya, Ivan D.
Volkow, Nora D.
PHARMACOLOGICAL RESEARCH, 2024, 200
[9] The Diminished Pipeline for Medications to Treat Mental Health and Substance Use Disorders
O'Brien, Peggy L.
Thomas, Cindy Parks
Hodgkin, Dominic
Levit, Katharine R.
Mark, Tami L.
PSYCHIATRIC SERVICES, 2014, 65 (12) : 1433 - 1438
[10] Confronting the challenge of failed translation in medications development for substance use disorders
Negus, S. S.
Banks, M. L.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2021, 210

← 1 2 3 4 5 →